Gefitinib Offers Modest Results in Esophageal Ca
VIENNA (MedPage Today) -- Treatment with gefitinib, a targeted EGFR inhibitor, failed to improve survival in advanced esophageal cancer but did slow disease progression, according to a study reported here.
